Monopar's Incredible Journey From $5 To $50 In Less Than 5 Months
From the brink of Nasdaq delisting last year due to non-compliance with the minimum bid price rule, this clinical-stage biotechnology ...
Hims & Hers Health down as Super Bowl ad draws controversy
An advocacy group criticizes Hims & Hers Health for allegedly misleading Super Bowl ad promoting weight loss products, ...
Lipella Pharmaceuticals Inc.: Lipella Pharmaceuticals Granted FDA Approval for Expanded Access Program for LP-310 in Oral Lichen Planus
Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) ("Lipella" or the "Company"), a clinical-stage biotechnology company focused on developing innovative therapies ...
Belite Bio: The Picture Is Still Unclear
Belite Bio is a biotech firm specializing in innovative therapies for retinal degenerative eye diseases with high unmet needs ...
Eton Pharmaceuticals Announces Extension of PDUFA Goal Date for ET-400
Eton Pharmaceuticals, Inc ("Eton" or the "Company") (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments ...
fnarena23h
Actinogen announces new and unique nonproprietary name of ’emestedastat’ for Xanamem
Actinogen Medical Limited (ASX: ACW) announces that the World Health Organization (WHO) has granted the nonproprietary name of ’emestedastat’ to Actinogen for its Xanamem ® /UE2343 once-a-day small ...